Neurosense Therapeutics is trading 5.19% lower at $4.20 after-hours, with no clear company-specific catalyst identified. - Shares closed September 30, 2026, at $4.43, down 7.32%; prior declines were 6.27% on September 29 and 26.62% on September 28. - A September 25 update reported progress toward a targeted December Canadian filing and first-half financial results; it does not explain the after-hours move. - Biotech stocks broadly slumped September 30, but evidence does not establish that sector weakness caused this move.